Beeler J A, van Wyke Coelingh K
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
J Virol. 1989 Jul;63(7):2941-50. doi: 10.1128/JVI.63.7.2941-2950.1989.
Eighteen neutralizing monoclonal antibodies (MAbs) specific for the fusion glycoprotein of the A2 strain of respiratory syncytial virus (RSV) were used to construct a detailed topological and operational map of epitopes involved in neutralization and fusion. Competitive binding assays identified three nonoverlapping antigenic sites (A, B, and C) and one bridge site (AB). Thirteen MAb-resistant mutants (MARMs) were selected, and the neutralization patterns of the MAbs with either MARMs or RSV clinical strains identified a minimum of 16 epitopes. MARMs selected with antibodies to six of the site A and AB epitopes displayed a small-plaque phenotype, which is consistent with an alteration in a biologically active region of the F molecule. Analysis of MARMs also indicated that these neutralization epitopes occupy topographically distinct but conformationally interdependent regions with unique biological and immunological properties. Antigenic variation in F epitopes was examined by using 23 clinical isolates (18 subgroup A and 5 subgroup B) in cross-neutralization assays with the 18 anti-F MAbs. This analysis identified constant, variable, and hypervariable regions on the molecule and indicated that antigenic variation in the neutralization epitopes of the RSV F glycoprotein is the result of a noncumulative genetic heterogeneity. Of the 16 eptiopes, 8 were conserved on all or all but 1 of 23 subgroup A or subgroup B clinical isolates.
使用18种针对呼吸道合胞病毒(RSV)A2株融合糖蛋白的中和单克隆抗体(MAb)构建了参与中和与融合的表位的详细拓扑和操作图谱。竞争性结合试验确定了三个不重叠的抗原位点(A、B和C)和一个桥接位点(AB)。选择了13个单克隆抗体抗性突变体(MARM),MAb与MARM或RSV临床毒株的中和模式确定了至少16个表位。用针对位点A和AB表位中六个表位的抗体选择的MARM表现出小噬斑表型,这与F分子生物活性区域的改变一致。对MARM的分析还表明,这些中和表位占据拓扑上不同但构象上相互依赖的区域,具有独特的生物学和免疫学特性。通过使用23株临床分离株(18株A亚组和5株B亚组)与18种抗F MAb进行交叉中和试验,检测了F表位的抗原变异。该分析确定了分子上的恒定、可变和高变区域,并表明RSV F糖蛋白中和表位的抗原变异是非累积性基因异质性的结果。在16个表位中,8个在23株A亚组或B亚组临床分离株的全部或除1株外的所有分离株上保守。